

Annaida Technologies SA closes oversubscribed Pre-Series A round to advance micro-Magnetic Resonance Spectroscopy

Lausanne, Switzerland - April 29, 2025 - Annaida Technologies, the first company to bring magnetic resonance to the scale of cells, announces the successful closing of its oversubscribed Pre-Series A funding round.

The round, led by **HEMEX**, saw the participation from existing investors including **Zürcher Kantonalbank (ZKB)**, **Excellis**, **EFI Lake Geneva Ventures**, and members of **Club degli Investitori** through Simon Fiduciaria. The capital raised, combined with the support from **EIC Transition (Horizon Europe)** and **Innosuisse (Swiss Innovation Project)**, places Annaida in a strong position to mature its groundbreaking micro magnetic resonance platform into a commercial product.

In addition to preparing for market entry in the fertility sector, the company is generating its first revenues through research product sales. Annaida's Embryospin platform is already being used in top ranked academic laboratories worldwide for advanced magnetic resonance research.

Annaida's proprietary technology has already demonstrated its potential in the fertility space, with additional future applications envisioned in the broader life sciences sector. With the ongoing projects and collaborations with top ranked universities, the funds will further support product development, regulatory validation, marketing and IP to consolidate the strategic company's position in existing and emerging markets.

"These resources will help us grow our R&D activities and collaborations and establish market presence, pushing us closer to our vision of turning micro magnetic resonance into a tool that expands the boundaries of science," said **Marco Grisi, Founder & CEO of Annaida**. *"Specifically, by applying it to pre-implantation embryo analysis, we aim to help reduce the number of miscarriages in assisted fertility and offer a brighter future to millions of families."*

"We've proudly supported Annaida Technologies since its inception in 2019," said **Pascal Winnen, HEMEX representative and member of Annaida's Board of Directors**. *"As an early-stage investor, we are highly impressed by the company's progress, the wide-ranging potential of its technology, particularly in the field of human fertility, and, above all, the team's consistent ability to meet ambitious milestones and create substantial value for shareholders."*

Giovanni Fazio, notable investor through the **Club degli Investitori**, with relevant expertise in healthcare strategy and commercialization, stated: *"The fertility rate in Europe has been decreasing steadily due to evolving social behaviors, and we will likely see similar trends in other regions worldwide in the coming years. Annaida's technology will offer millions of women access to a treatment that not only improves the success rates of assisted reproduction but also protects the integrity of the embryo by avoiding invasive biopsies. We are convinced that Annaida will bring tremendous value to both providers and patients, significantly enhancing assisted reproduction processes and ultimately establishing itself as a recognized leader in this space."*

About Annaida Technologies

Born as a spin-off from EPFL, **Annaida Technologies** is now one of Europe's most promising deep tech startups, pioneering **micro magnetic resonance spectroscopy (micro-MRS)** to enable non-invasive chemical analysis at microscopic scales. With initial applications in fertility and life sciences, Annaida is on a mission to transform micro-MRS into a platform for discovery, shifting the paradigm in how we assess and understand living systems at their earliest and most challenging stages.

About Investors in the Pre-Series A Round:

- **HEMEX**
HEMEX is a leading European investment firm specializing in healthcare and medtech startups with domain expertise. They provide capital to high-potential ventures at the intersection of technology and medicine, aiming to transform the future of healthcare.
[Learn more about HEMEX](#)
- **Club degli Investitori**
Club degli Investitori is an Italian business angel network focused on identifying and nurturing high-potential startups. They connect visionary entrepreneurs with investors to accelerate the growth of innovative companies in various industries.
[Learn more about Club degli Investitori](#)
- **Zürcher Kantonalbank (ZKB)**
Zürcher Kantonalbank (ZKB) is one of the largest and most trusted financial institutions in Switzerland. With a deep commitment to supporting innovation, ZKB invests in high-growth companies across various industries, including life sciences and technology.
[Learn more about ZKB](#)
- **EFI Lake Geneva Ventures**
EFI Lake Geneva Ventures is a seed and early-stage investment firm based in Geneva, Switzerland. Its mission is to foster innovation by investing at an early stage in fast-growing innovative Swiss companies in Technology, Life Sciences and Medtech. Their target is deep tech innovations.
[Learn more about EFI Lake Geneva Ventures](#)
- **Excellis**
Excellis is a global investment firm focusing on cutting-edge innovations in deep tech, clean tech, and med tech. They actively support companies that push the boundaries of science and technology to create a lasting impact. Their focus is for Italian entrepreneurs based outside the country.
[Learn more about Excellis](#)